Clinical evaluation of adriamycin, a new antitumour antibiotic.
about
Cancer chemotherapy: past, present, and future--Part ICancer chemotherapy--the first twenty-five yearsA Biophysical Systems Approach to Identifying the Pathways of Acute and Chronic Doxorubicin Mitochondrial CardiotoxicityApigenin Attenuates Adriamycin-Induced Cardiomyocyte Apoptosis via the PI3K/AKT/mTOR Pathway.Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin's lymphoma.Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin.A preliminary trial of doxorubicin in advanced breast cancer and other malignant disease.Clinical trials in the non-Hodgkin's lymphomata at Stanford University experimental design and preliminary resultsCardiac systolic dysfunction in doxorubicin-challenged rats is associated with upregulation of MuRF2 and MuRF3 E3 ligasesChemotherapy for early-stage breast cancer: a brief history.Encapsulation of adriamycin in human erythrocytes.Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury.Mitoxantrone, More than Just Another Topoisomerase II Poison.Anthraquinones As Pharmacological Tools and Drugs.The persistence of adriamycin in man and rat.Syntheses of 2-substituted 1-amino-4-bromoanthraquinones (bromaminic acid analogues) - precursors for dyes and drugs.The influential and inspirational Gianni Bonadonna's life commitment to evidence-based cancer medicine.Fabrication of an electrochemical sensor for determination of doxorubicin in human plasma and its interaction with DNA.DNA-binding studies of valrubicin as a chemotherapy drug using spectroscopy and electrochemical techniques.Adriamycin in the treatment of acute leukaemia.Treatment of acute myeloblastic leukaemia with RP 22050.Update on adjuvant chemotherapy for early breast cancerAcylated and unacylated ghrelin inhibit doxorubicin-induced apoptosis in skeletal muscle
P2860
Q24657512-38063AB1-EE9C-4718-B86C-01F9BA306834Q24681789-8ED69C9C-2BE4-4072-8FDC-BE158CEBEA13Q28553631-A04E76AC-FD81-4618-BE9F-143BAD31EB55Q33823153-858DFFEF-6999-4642-B88B-DB89EA843DEBQ34269228-1D82B1C6-D135-4864-87BA-87AB9441AD61Q35550223-853415A6-1D53-4C06-BA58-FE93A10DEC24Q36040540-31587DEA-8143-4862-808C-CC0A391A0631Q36291092-4851AFFB-21BE-4D8E-93FC-FD6B58350F8CQ36772298-0CCEE9A1-B957-492A-A368-E09A21EE56F0Q37363341-94AC1755-FCFF-4ADB-BEAB-C430EE522B9EQ37399860-7CC48397-8185-4F91-8AB9-727A569C3C0FQ38166071-BFFC3D52-498D-49B0-98DE-0A37FA83B1F4Q38569206-68182EAE-7B27-4FB4-8A0A-E8FA6C0D7A14Q38816745-3C9C8C92-8FBF-4F21-8041-1D2D812BDBA1Q41785981-1636412B-BC8D-450A-B950-A891474386CEQ41952614-320CD24C-0771-4F01-B8AA-D07551A0CF1EQ47616724-AA40C6AD-DA54-42B9-B877-56117A411331Q49398803-7EB62B64-F21F-427C-AFA8-47A78C20A45BQ50142532-C2B0EE02-9FD5-4C13-B0C7-44EA121693A5Q53710205-3352347A-9DF9-4F3F-83D4-F8993E4E5F46Q54654974-F0F100AA-4629-44D9-96C7-7FB5755E99DCQ57126532-79FFD9F7-2FC2-4424-8379-0A2E8D15E597Q57278903-DDA7465F-84DC-46BA-94C0-FD5B5D11E0D1
P2860
Clinical evaluation of adriamycin, a new antitumour antibiotic.
description
1969 nî lūn-bûn
@nan
1969年の論文
@ja
1969年学术文章
@wuu
1969年学术文章
@zh
1969年学术文章
@zh-cn
1969年学术文章
@zh-hans
1969年学术文章
@zh-my
1969年学术文章
@zh-sg
1969年學術文章
@yue
1969年學術文章
@zh-hant
name
Clinical evaluation of adriamycin, a new antitumour antibiotic.
@en
Clinical evaluation of adriamycin, a new antitumour antibiotic.
@nl
type
label
Clinical evaluation of adriamycin, a new antitumour antibiotic.
@en
Clinical evaluation of adriamycin, a new antitumour antibiotic.
@nl
prefLabel
Clinical evaluation of adriamycin, a new antitumour antibiotic.
@en
Clinical evaluation of adriamycin, a new antitumour antibiotic.
@nl
P2093
P2860
P356
P1433
P1476
Clinical evaluation of adriamycin, a new antitumour antibiotic.
@en
P2093
Bonadonna G
Fossati-Bellani F
Monfardini S
P2860
P304
P356
10.1136/BMJ.3.5669.503
P407
P577
1969-08-01T00:00:00Z